Other formats:
BibTeX
LaTeX
RIS
@misc{2365862, author = {Žáčková, Daniela}, booktitle = {29th meeting of the European Investigators on CML (EI-CML)}, keywords = {chronic myeloid leukemia; TFR; HALF; CLINICAL TRIAL}, language = {eng}, title = {Why are not all eligible CML patients willing to attempt TFR? A nationwide analysis related to the TKI stopping trail HALF}, url = {https://www.infocongressi.com/congressi-medici-2023/29th-meeting-of-the-european-investigators-on-chronic-myeloid-leukemia-ei-cml#gsc.tab=0}, year = {2023} }
TY - SLIDE ID - 2365862 AU - Žáčková, Daniela PY - 2023 TI - Why are not all eligible CML patients willing to attempt TFR? A nationwide analysis related to the TKI stopping trail HALF KW - chronic myeloid leukemia KW - TFR KW - HALF KW - CLINICAL TRIAL UR - https://www.infocongressi.com/congressi-medici-2023/29th-meeting-of-the-european-investigators-on-chronic-myeloid-leukemia-ei-cml#gsc.tab=0 N2 - A prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission The HALF clinical trial is designed as a prospective, multicenter, nonrandomized, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after a prior two-step dose reduction in patients with chronic myeloid leukemia in deep remission. The clinical evaluation of HALF could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves, but also for the healthcare system. ER -
ŽÁČKOVÁ, Daniela. Why are not all eligible CML patients willing to attempt TFR? A nationwide analysis related to the TKI stopping trail HALF. In \textit{29th meeting of the European Investigators on CML (EI-CML)}. 2023.
|